$58.4 Million is the total value of AJU IB Investment Co., Ltd.'s 7 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ARCELLX INC | $25,919,000 | +3.8% | 1,380,890 | 0.0% | 44.37% | -8.2% | ||
RALLYBIO CORP | $10,920,000 | +91.6% | 754,678 | 0.0% | 18.69% | +69.5% | ||
KYMR | KYMERA THERAPEUTICS INC | $9,950,000 | +10.6% | 457,059 | 0.0% | 17.03% | -2.2% | |
SEER | SEER INC | $6,319,000 | -13.5% | 816,375 | 0.0% | 10.82% | -23.5% | |
RAPT | RAPT THERAPEUTICS INC | $2,394,000 | +31.8% | 99,503 | 0.0% | 4.10% | +16.6% | |
XILIO THERAPEUTICS INC | $1,943,000 | -0.4% | 667,742 | 0.0% | 3.33% | -11.9% | ||
STRO | SUTRO BIOPHARMA INC | $971,000 | +6.5% | 175,000 | 0.0% | 1.66% | -5.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2022-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
KYMERA THERAPEUTICS INC | 8 | Q3 2022 | 40.4% |
SEER INC | 8 | Q3 2022 | 25.9% |
RAPT THERAPEUTICS INC | 8 | Q3 2022 | 5.1% |
SUTRO BIOPHARMA INC | 8 | Q3 2022 | 3.6% |
ATEA PHARMACEUTICALS INC | 4 | Q3 2021 | 47.7% |
APELLIS PHARMACEUTICALS INC | 4 | Q3 2021 | 38.8% |
RALLYBIO CORP | 4 | Q3 2022 | 18.7% |
XILIO THERAPEUTICS INC | 4 | Q3 2022 | 14.9% |
CLEARSIDE BIOMEDICAL INC | 4 | Q3 2021 | 1.1% |
MOLECULAR TEMPLATES INC | 4 | Q3 2021 | 1.0% |
View AJU IB Investment Co., Ltd.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR/A | 2022-11-14 |
13F-HR | 2022-11-07 |
13F-HR | 2022-08-09 |
13F-HR | 2022-05-12 |
13F-HR | 2022-02-09 |
13F-HR | 2021-11-10 |
13F-HR | 2021-08-10 |
13F-HR | 2021-05-12 |
13F-HR | 2021-05-12 |
4 | 2017-11-13 |
View AJU IB Investment Co., Ltd.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.